Dual tracer 11C-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment.

Abstract

PURPOSE:

The purpose of this study was to evaluate a dual tracer 2-deoxy-2-[F-18]fluoro-D: -glucose (FDG) and (11)C-choline positron emission tomography (PET) protocol in the detection of biochemical prostate cancer relapse.

PROCEDURES:

Seventy-three patients (median Prostate Specific Antigen (PSA) Test value 2.7 ng/ml (1.1-5.4)) after radical treatment. PET scans were performed by means of a ECAT-Exact HR+ in the first 18 patients and in a PET/computed tomography Biograph II in the remaining 55 patients.

RESULTS:

The sensitivity of (11)C-choline and FDG was 60.6% and 31%. In PSA levels over 1.9 ng/ml, sensitivity increased to 80% and 40%, respectively. In the group receiving adjuvant hormone therapy, the diagnostic yields were 71.2% and 43%, respectively. While (11)C-choline-PET could not differentiate well and poorly differentiated Gleason score patients, FDG-PET results were almost significant (p = 0.058).

CONCLUSIONS:

A PSA value higher than 1.9 ng/ml determines a significant increase in the diagnostic yield. Adjuvant hormonotherapy has no influence on the PET results. FDG has a better correlation with the Gleason score than (11)C-choline.

• Authors: José A Richter, Macarena Rodríguez, Jorge Rioja, Iván Peñuelas, Josep Martí-Climent, Puy Garrastachu, Gemma Quincoces, Javier Zudaire, María J García-Velloso
• Journal: Molecular imaging and biology (Mol Imaging Biol) Vol. 12 Issue 2 Pg. 210-7 (Apr 2010) ISSN: 1860-2002 [Electronic] United States
• PMID: 19543774 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Carbon Radioisotopes
• Fluorodeoxyglucose F18
• Prostate-Specific Antigen
• Choline

Topics

• Adult
• Aged
• Carbon Radioisotopes
• Choline
• Fluorodeoxyglucose F18
• Humans
• Male
• Middle Aged
• Neoplasm Recurrence, Local (diagnostic imaging)
• Positron-Emission Tomography
• Prostate-Specific Antigen (blood)
• Prostatic Neoplasms (blood, diagnostic imaging, therapy)